Suppr超能文献

儿童心脏移植受者中移植后淋巴细胞增生性疾病(PTLD)亚型与临床结局的关系:一项对558例患者的回顾性单机构分析/经验

Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients.

作者信息

Liu Yan, Wang Billy C, Zuppan Craig W, Chau Peter, Fitts James, Chinnock Richard, Wang Jun

机构信息

Department of Pathology and Laboratory Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA.

Division of Pediatric Critical Care, Department of Pediatrics, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.

出版信息

Cancers (Basel). 2023 Feb 3;15(3):976. doi: 10.3390/cancers15030976.

Abstract

Post-transplant lymphoproliferative disorders (PTLD) are heterogenous lymphoproliferative disorders that develop as a consequence of immunosuppression in transplant recipients. We sought to determine if subtypes of PTLD correlated with different outcomes. We performed a retrospective review of PTLD occurring in pediatric heart transplant recipients. A total of 558 children and infants underwent cardiac transplantation at our institution between 1985 and 2019 and were followed until March 2021. Forty-nine of 558 patients developed PTLD (8.8%). As compared to older children (>one year of age), infant recipients (<three months of age) were less likely to develop PTLD. Monomorphic PTLDs (M-PTLD, 61%) was the most common subtype at initial diagnosis, followed by non-destructive (21%), polymorphic (14%), and classic Hodgkin lymphoma (cHL, 4%). Patients who underwent transplantation at a young age (<three months) had significantly lower rates of M-PTLD or cHL and a longer time from transplant to PTLD diagnosis as compared to children older than one year at transplant ( = 0.04). Although not reaching statistical significance, patients with a shorter time to PTLD diagnosis showed a trend toward higher rates of M-PTLD or cHL. As expected, the overall survival (OS) of patients with M-PTLD or cHL was significantly lower than patients with non-destructive or polymorphic PTLD.

摘要

移植后淋巴细胞增生性疾病(PTLD)是移植受者因免疫抑制而发生的异质性淋巴细胞增生性疾病。我们试图确定PTLD的亚型是否与不同的预后相关。我们对小儿心脏移植受者中发生的PTLD进行了回顾性研究。1985年至2019年间,共有558名儿童和婴儿在我们机构接受了心脏移植,并随访至2021年3月。558例患者中有49例发生了PTLD(8.8%)。与大龄儿童(>1岁)相比,婴儿受者(<3个月)发生PTLD的可能性较小。单形性PTLD(M-PTLD,61%)是初始诊断时最常见的亚型,其次是非破坏性(21%)、多形性(14%)和经典霍奇金淋巴瘤(cHL,4%)。与移植时年龄大于1岁的儿童相比,年龄较小(<3个月)接受移植的患者发生M-PTLD或cHL的比率显著较低,从移植到PTLD诊断的时间更长(P = 0.04)。尽管未达到统计学意义,但PTLD诊断时间较短的患者显示出M-PTLD或cHL发生率较高的趋势。正如预期的那样,M-PTLD或cHL患者的总生存率(OS)显著低于非破坏性或多形性PTLD患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5547/9913467/1885856a3f20/cancers-15-00976-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验